Neuroscience
-
A novel trial is set to investigate the popular yet still deeply unproven practice of microdosing psychedelics, and promises to be the first exploration of naturalistic psilocybin microdosing in a lab-setting using a cutting-edge neuroimaging technique.
-
A new study describes one way immune cells become dysfunctional as we age, leading to the inflammatory hyperdrive that plays a role in most age-related disease from cancer to cognitive decline, and suggests this immune dysfunction can be reversed.
-
Australian scientists have developed a world-first test claimed to accurately measure levels of a brain protein associated with depression and bipolar disorder. The test could offer doctors an objective diagnostic tool to assess patients.
-
A pair of newly published studies are offering novel insights into how the neurodegeneration associated with Parkinson’s disease leads to cognitive decline. The research suggests minor vision problems can precede cognitive decline by up to 18 months.
-
German scientists have restored the ability to walk in mice that had been paralyzed by a complete spinal cord injury. The team created a “designer” signaling protein and injected it into the animals’ brains, stimulating nerve cells to regenerate.
-
A team of scientists has demonstrated a novel microencapsulation method designed to improve the absorption and bioavailability of CBD. Animal tests suggest the new method increases peak concentrations of CBD in the brain by 300% compared to CBD oil.
-
Although yet to be published in a peer-reviewed journal, pharmaceutical company Eli Lilly has announced promising results from one of its Phase 2 human trials testing an experimental Alzheimer’s disease drug designed to slow cognitive decline.
-
A robust new study has comprehensively demonstrated how SARS-CoV-2, the coronavirus that causes COVID-19, can infect the brain and central nervous system. The study validates a growing body of research attributing neurological issues to COVID-19.
-
A new study has identified three different molecular subtypes of Alzheimer's disease. The research suggests these subtypes are so distinct from one another they could account for previous clinical trial failures and inconsistent translational studies.
-
Parkinson’s disease is characterized by clumps of misfolded proteins accumulating and killing brain cells. Johns Hopkins researchers have developed an artificial enzyme that may stop these clumps from spreading, providing a new potential treatment.
-
Two observational studies have found a link between e-cigarette use and cognitive complaints such as memory impairments and brain fog. The research doesn't present evidence of a causal link but calls for further long-term study into the relationship.
-
Japanese mathematician Kokichi Sugihara has won the annual Illusion of the Year Contest with a fascinating 3D model of a nearly 200-year old 2D illusion. The contest, run by the UK-based Neural Correlate Society has been bending brains for 16 years.